Topiroxostat

Drug Profile

Topiroxostat

Alternative Names: FYX-051; SK-0910; Topiroric; Uriadec

Latest Information Update: 27 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fuji Yakuhin
  • Developer Fuji Yakuhin; Sanwa Kagaku Kenkyusho
  • Class Nitriles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Xanthine dehydrogenase inhibitors; Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout; Hyperuricaemia
  • Phase II Diabetic nephropathies

Most Recent Events

  • 01 Dec 2016 Sanwa Kagaku Kenkyusho and Fuji Yakuhin completes the phase II UPWARD trial for Diabetic nephropathy, hyperuricaemia and gout in Japan (NCT02327754)
  • 01 Mar 2015 Phase-II clinical trials in Diabetic nephropathies in Japan (PO) (NCT02327754)
  • 01 Mar 2015 Sanwa Kagaku Kenkyusho and Fuji Yakuhin initiates enrolment in the phase II UPWARD trial for Gout and hyperuricaemia in Japan (NCT02327754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top